Skip to main content
. 2016 Feb 12;7(10):11708–11723. doi: 10.18632/oncotarget.7336

Figure 5. Lip-FLLL32 sensitizes pancreatic cancer to chemo/radiotherapy.

Figure 5

(A) Cytotoxicity of Gemcitabine combination with free FLLL32 (left) or Lip-FLLL32 (right) against PANC-1 cells. (B) Clonogenic survival assay of PANC-1 cells treated by FLLL32, radiotherapy or their combination. Survival fractions were plotted, and the enhancement ratios (ER) by FLLL32 or Lip-FLLL32 were calculated vs. DMSO. (C) PANC-1 xenograft nude mice were treated with empty liposome, 2 Gy radiation, 15 mg/kg Lip-FLLL32 or combination three times a week for three weeks. Tumor growth curves of mice were plotted up to Day 43. The data are mean ± SEM (n = 9). ***P < 0.001, two-way ANOVA, by comparing Radiation, Lip-FLLL32 or combination treated group with Lip only group at day 25; a, P < 0.001, two-way ANOVA, by comparing combination group with Radiation group. (D) Kaplan-Meier analysis of tumor size doubling time of mice in four groups. The medium doubling time for Lip only, Radiation, Lip-FLLL32 and combination treated groups is 15, 22, 22 and 43, respectively. **P < 0.01, ***P < 0.001, log-rank test, by comparing three other groups with untreated control group.